Prediction of Delayed Toxic Cardiomyopathy in Children

ANTHRA GROUP Inclusion Criteria: * Patients who were treated with anthracyclines for malignant disease between the ages of 0 and 18 * Patient aged 11 to 27 years * Included in the "SpeckleAnthra" Study (NCT02893787) * Discontinued chemotherapy for more than 6 years * Patient in remission of malignant disease * Enrolled in a social security plan * Written informed consent from at least one legal representative for the minor patient/ Written informed consent for patients of legal age Exclusion Criteria: * Onset of active malignancy or recurrence of malignancy after the "Speckle Anthra" study that required resumption of chemotherapy or mediastinal radiotherapy. * Chronic cardiac, pulmonary or muscular pathology of etiology other than secondary to anthracycline therapy * For adult patients: subject under guardianship or curators CONTROL GROUP Inclusion Criteria: * Control patient included in the "Speckle Control" study (NCT02056925) * Had a cardiological consultation with echocardiography performed for a banal reason (heart murmur test, cardiological symptoms) and whose result was normal * No chronic disease or long-term drug treatment Exclusion Criteria: * Refusal to participate in the study by the patient and/or parents or legal guardian after receipt of the study's information and non-objection note.